A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer

Curr Cancer Drug Targets. 2020;20(5):325-334. doi: 10.2174/1568009620666200228123754.

Abstract

Cancer is still a serious public issue that humans face. Chemoresistance is one of the most important reasons for relapse and poor prognosis. The accumulated data support that the polymorphisms in IGF1 are correlated with both circulating IGF1 levels and cancer risk and activation of IGF1signaling enhances the progression of cancer. Here, we emphasize the role of IGF1 in resistance to various chemotherapies. Dysregulation of IGF1-related lncRNAs may also play an important role in the regulation of chemoresistance by IGF1. Finally, targeting the IGF1 pathway and lncRNAs is effective for increasing the sensitivity of cancer cells to chemotherapies. More basic and clinical studies need to be conducted to investigate the value of targeting IGF1 and IGF1-related lncRNAs in restoring sensitivity to chemotherapies.

Keywords: Cancer; IGF1; chemoresistance; chemotherapy; lncRNAs; therapy..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Drug Resistance, Neoplasm*
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • RNA, Long Noncoding / genetics*

Substances

  • Antineoplastic Agents
  • RNA, Long Noncoding
  • Insulin-Like Growth Factor I